Fibrin formation and turnover are intimately associated with inflammation and wound healing. To explore whether fibrin(ogen)-derived peptides exert direct effects upon cells involved in inflammation and tissue repair we examined the capacity of human fibrinopeptide B (hFpB), a thrombin-derived proteolytic cleavage product of the fibrinogen B beta-chain, to stimulate neutrophils (PMN), monocytes, and fibroblasts. hFpB caused directed cell migration of PMN and fibroblasts that was optimal at approximately 10(-8) M. This chemotactic activity was blocked by preincubating hFpB with antiserum to hFpB. hFpB was not chemotactic for monocytes. The chemotactic potency of hFpB for PMN was equivalent to that of anaphylatoxin from the fifth component of human complement (C5a), leukotriene B4 (LTB4), and formyl-methionyl-leucyl-phenylalanine (fMLP), and for fibroblasts its chemotactic activity was comparable to that of platelet-derived growth factor. hFpB did not interact with PMN receptors for C5a, LTB4, or fMLP as (a) desensitization with 10(-7) M hFpB abolished chemotaxis to hFpB but had no effect upon chemotaxis to C5a, LTB4, or fMLP and (b) induction of chemotactic responses to fMLP and LTB4 in neutrophilic leukemic cells (HL-60 cells) by incubation with dimethylsulfoxide did not extend to hFpB. Like fMLP, hFpB caused a rapid, dose-dependent increase in PMN cytoskeletal associated actin, but unlike fMLP, hFpB did not cause PMN aggregation, release of lysosomal enzymes (lysozyme and beta-glucuronidase), or the production […] migration of PMN and fibroblasts that was optimal at -810 M. This chemotactic activity was blocked by preincubating hFpB with antiserum to hFpB. hFpB was not chemotactic for monocytes. The chemotactic potency of hFpB for PMN was equivalent to that of anaphylatoxin from the fifth component of human complement (C5a), leukotriene B4 (LTB4), and formyl-methionylleucyl-phenylalanine (fMLP), and for fibroblasts its chemotactic activity was comparable to that of platelet-derived growth factor. hFpB did not interact with PMN receptors for C5a, LTB4, or fMLP as (a) desensitization with 10-7 M hFpB abolished chemotaxis to hFpB but had no effect upon chemotaxis to C5a, LTB4, or fMLP and (b) induction of chemotactic responses to fMLP and LTB4 in neutrophilic leukemic cells (HL-60 cells) by incubation with dimethylsulfoxide did not extend to hFpB. Like fMLP, hFpB caused a rapid, dose-dependent increase in PMN cytoskeletal associated actin, but unlike fMLP, hFpB did not cause PMN aggregation, release of lysosomal enzymes (lysozyme and ,l-glucuronidase), or the production of superoxide anion.
Introduction
Fibrin has long been recognized as a histologic feature of both acute and chronic inflammatory processes. While the role of fibrin deposition in inflammatory lesions is not yet well understood, its presence does not appear to be incidental. Fibrin formation is necessary for the full development of delayed hypersensitivity reactions (1, 2) . Moreover, fibrin(ogen)-derived proAddress correspondence to Dr. Senior Receivedfor publication 25 September 1985. teolytic fragments have been found to produce many effects relevant to inflammation that include changes in vascular tone (3) and permeability (4) , retraction (5) and disorganization of endothelial cells (6) , suppression of lymphocyte proliferation (7) , and chemotaxis of inflammatory cells (4, (8) (9) (10) .
Human fibrinopeptide B (hFpB),' a peptide of 14 amino acids released from the amino-terminus of the B 3-chains of fibrinogen by thrombin and also contained within the primary plasmin cleavage product of fibrinogen, B i# , has been reported to have chemotactic activity for neutrophils (PMN) (10, 1 1). The present study extends these data, showing that the chemotactic activity ofhFpB does not involve the receptors involved in responses to anaphylatoxin from the fifth component of human complement (C5a) (12) , leukotriene B4 (LTB4) ( 13) , or formyl-methionyl-leucyl-phenylalanine (fMLP) (14) . Like fMLP, hFpB was found to increase the amount of actin associated with the cytoskeleton, but unlike fMLP it did not cause PMN aggregation, release of lysosomal enzymes or the production of superoxide anion. Fibroblasts were also found to demonstrate chemotactic responses to hFpB, suggesting that the effects of this fibrinopeptide extend to cell types other than inflammatory cells.
Methods
Reagents. hFpB was purchased from Bachem Inc., Fine Chemicals (Torrance, CA), and hFpB without its carboxy-terminus arginine (hFpB des Arg) was prepared by solid-phase peptide synthesis (15 (18) , and were used between the second and sixth passages.
Chemotaxis. Chemotaxis was determined in modified Boyden chambers, as previously described (19, 20 In experiments to assess the effects of anti-hFpB IgG, hFpB was incubated with anti-hFpB IgG for 1 h and then used in the chemotaxis assay in the standard manner. Control measurements were made using the same concentration of the IgG incubated with fMLP.
To assess whether hFpB utilizes receptors involved in chemotaxis to C5a, LTB4 or fMLP, two approaches were used: (a) desensitization in which PMN were incubated with hFpB, 10-7 M, for 30 min at room temperature, washed gently once, and then tested for chemotactic responsiveness to hFpB, fMLP, LTB4, or C5a; and (b) HL-60 cells were tested for chemotaxis to fMLP, LTB4, and hFpB before and after exposure to DMSO, 1.12% vol/vol, for 96 h, conditions known to induce chemotactic responsiveness to fMLP (14) .
Other assays. Cytoskeletal-associated actin was measured by the method of White et al. (21) . Briefly, 1 X I07 PMN were prewarmed to 37°C before the addition oftest agents. Ice-cold Triton X-100 was added at time points from 15 s to 10 min after addition of the test agents. The cell lysates were kept on ice for an additional 10 min, then centrifuged (8,000 X g, 4 min 4C) to pellet the cytoskeleton. The pellet was solubilized in 50 Ml of denaturing solution and electrophoresis was performed with a 6-12% polyacrylamide gradient. After staining with Coomassie Blue, the gel was scanned for the intensity of the actin band (42 kD) (Ultrascan, model 2202; LKB Instruments, Inc., Gaithersburg, MD). PMN aggregation was performed as described by Craddock et al. (22) . Accordingly, PMN, 2 X 106/ml, were stirred at 1,200 rpm at 37°C in a cuvette in an aggregometer (model 300; Chrono-Log Corp., Havertown, PA) and the change in light transmission was monitored continuously after addition of either hFpB or known PMN aggregants.
PMN lysosomal enzyme release was determined by measuring ,-glucuronidase and lysozyme activities in Hank's balanced salt solution after exposure of PMN to hFpB or other agents in the presence or absence ofcytochalasin B (5 Mg/ml for 5 min at 37°C) (23) . Release was expressed as a percentage of the total (100%) cellular enzyme activity liberated from the cells by 1% (vol/vol) Triton X-100. The generation of superoxide anion was determined by reduction of cytochrome c in the presence and absence of superoxide dismutase (24) .
Results
Chemotactic activity of hFpB. As shown in Fig. 1 , hFpB stimulated migration of PMN, with a peak effect occurring at 10-8 M. In contrast, hFpB exerted no effect upon the migration of monocytes under conditions in which monocyte responses occurred, 100 cells per HPG at l0-`M fMLP (data not shown). The stimulation of PMN migration by hFpB was chemotactic as seen by checkerboard analysis (Table I ). The chemotactic activity of hFpB was blocked by anti-hFpB IgG (Fig. 2) . The effect of the anti-hFpB IgG was specific for hFpB and did not involve a toxic effect upon the cells as the same concentration of antibody had no effect upon PMN chemotaxis to fMLP. The magnitude of the chemotactic response of PMN to hFpB was comparable to that achieved with C5a, LTB4, and fMLP (Fig.  3) . hFpB displayed the same without its carboxy-terminus ar- ginine chemotactic activity as hFpB, indicating that the carboxyterminus arginine is not crucial to the activity of the peptide (data not shown).
Pre-exposure of PMN to hFpB at 10-7 M abolished the subsequent responsiveness of the cells to hFpB, but other cells similarly exposed to hFpB retained full responsiveness to C5a, LTB4, and fMLP (Fig. 4 (Fig. 6 A) . The response was not as prominent as that observed with fMLP, but it showed a clear dose response with the maximal effect at 10-8 M (Fig. 6 B) .
PMN did not aggregate in response to hFpB over the concentration range 10-l-10-1o M, although under identical con- ditions typical aggregation responses were observed with both C5a and fMLP.
There was no detectable production ofsuperoxide anion after exposure ofPMN to hFpB, although such production was readily observed when the cells were stimulated with fMLP (Table III) . PMN which had been exposed to cytochalasin B did not release either lysozyme or f3-glucuronidase in response to hFpB, even at concentrations 10-fold greater than the optimal concentration of hFpB for chemotaxis, while fMLP caused substantial release of both enzymatic activities.
Discussion
Clot formation begins with activation of the intrinsic or extrinsic coagulation pathways leading to generation of the prothrombin activation complex (prothrombinase) (26) . Thrombin produced from these reactions catalyzes the conversion of fibrinogen to fibrin and stimulates platelet activation and the platelet release reaction. Coincident with fibrin formation and platelet activa- tion, a variety ofchemotactic and growth promotion substances are released, including complement fiagments (27, 28) , proteases (29), and platelet proteins such as platelet factor 4 and PDGF (19, 25, 30) . Once formed, the fibrin clot undergoes remodeling by proteolysis, notably through the actions of plasmin (31) and PMN elastase (32) . Thus, substances released during clot formation, platelet activation, and clot resolution have the capacity to recruit inflammatory cells and other cell types including fibroblasts, and also to exert mitogenic activity. This indicates that fibrin clot formation should be viewed as a dynamic process that involves not only hemostatic functions but also as one that generates a number of substances that are known to play important roles in inflammation and wound healing (Fig. 7) . Possibly even more important than the release ofbiologically active substances from the site of fibrin formation is the fact that fibrin clots have the potential to hold active compounds in the fluid phase of the fibrin gel and shield them from inhibitors and metabolic turnover. (12) (13) (14) .
The present results further demonstrate that the chemotactic activity of hFpB extends to fibroblasts. In this respect, hFpB has activity similar to several platelet alpha granule proteins (30) , extracellular matrix components including fibronectin (40), collagen (41) and elastin peptides (20), factors from lymphocytes (42) , and from C5 (43) . This finding suggests that hFpB, and possibly other fibrin degradation products, contribute to mesenchymal cell recruitment at sites of inflammation and injury.
Two compelling pieces of information indicate that PMN chemotaxis to hFpB does not involve receptors involved in PMN responses to C5a (12), LTB4 (13), or fMLP (14) . First, desensitization of PMN with hFpB abolished the response of the cells to hFpB without affecting their chemotactic responses to these other chemotactic factors. The fact that desensitization to chemotactic factors is factor-specific has been shown by others (44, 45) . Second, HL-60 cells, upon exposure to DMSO, were found to develop chemotactic responsiveness to two chemotactic factors, fMLP and LTB4, but not to hFpB. Apart from providing further evidence that chemotaxis to hFpB is not mediated by receptors for either fMLP or LTB4, these data suggest that PMN do not acquire responsiveness to all potential chemoattractants simultaneously during development. Kay et al. reported that hFpB is chemotactic for monocytes (10). This was not confirmed in the present experiments. There is no obvious explanation for the discrepancy, but it may be noted that chemotactic activity for one type of leukocyte is not necessarily shared by other types of leukocytes. For example, C5a without its carboxy-terminus arginine is as active as C5a for monocytes but much weaker than C5a for PMN (46) . Also, thrombin, which is chemotactic for monocytes, is inactive against PMN (47) .
A most interesting finding about the effect of hFpB upon PMN is its capacity to cause actin polymerization and to elicit a potent chemotactic response without causing aggregation, the release of lysosomal enzymes, or the production of superoxide anion. In this respect, hFpB contrasts with C5a, fMLP, or LTB4 and resembles instead a factor generated from plasma by superoxide (48) and the synthetic tripeptide, gly-his-gly (49) , which also causes PMN chemotaxis without causing PMN secretory responses.
That PMN chemotactic factors do not always cause lysosomal enzyme release has been supported by other evidence. Snyderman and colleagues have shown that exposure of PMN to certain aliphatic alcohols enhances chemotactic responses while depressing specific granule secretion (50) . An interesting example of dissociation of enzyme secretion and chemotaxis was found with equine PMN (51) . These cells were observed to bind fMLP and secrete lysosomal enzymes in response to fMLP but failed to show chemotaxis to fMLP.
Not only are chemotaxis and lysosomal enzyme secretion separable in response to some agents, but enzyme release and superoxide production have also been dissociated in studies of rat PMN (52) . Moreover, even with the same PMN response, superoxide anion production, multiple pathways appear to exist (53 
